Nanjing Vazyme Biotech Co Ltd (688105) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.020x

Based on the latest financial reports, Nanjing Vazyme Biotech Co Ltd (688105) has a cash flow conversion efficiency ratio of 0.020x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥75.30 Million ≈ $11.02 Million USD) by net assets (CN¥3.84 Billion ≈ $562.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Nanjing Vazyme Biotech Co Ltd (688105) total market value for the company's overall valuation and market capitalisation.

Nanjing Vazyme Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2025)

This chart illustrates how Nanjing Vazyme Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Nanjing Vazyme Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Nanjing Vazyme Biotech Co Ltd ranked by their cash flow conversion efficiency. Explore earnings quality score of Nanjing Vazyme Biotech Co Ltd to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
GIMV NV
BR:GIMB
-0.116x
Gestamp Automocion SA
MC:GEST
0.122x
EQ Resources Ltd
AU:EQR
-0.169x
Northking Information Technology Co
SHE:002987
0.027x
Progress Software Corporation
NASDAQ:PRGS
0.156x
Grupo Televisa SAB ADR
NYSE:TV
0.029x
Pfeiffer Vacuum Technology AG
F:PFV
0.099x
Republic Bancorp Inc
NASDAQ:RBCAA
0.001x

Annual Cash Flow Conversion Efficiency for Nanjing Vazyme Biotech Co Ltd (2017–2025)

The table below shows the annual cash flow conversion efficiency of Nanjing Vazyme Biotech Co Ltd from 2017 to 2025. View Nanjing Vazyme Biotech Co Ltd stock quote for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CN¥3.79 Billion
≈ $554.78 Million
CN¥233.16 Million
≈ $34.12 Million
0.061x +2605.02%
2024-12-31 CN¥3.94 Billion
≈ $577.07 Million
CN¥-9.68 Million
≈ $-1.42 Million
-0.002x -104.99%
2023-12-31 CN¥4.03 Billion
≈ $589.61 Million
CN¥198.40 Million
≈ $29.03 Million
0.049x -69.11%
2022-12-31 CN¥4.61 Billion
≈ $674.90 Million
CN¥735.17 Million
≈ $107.58 Million
0.159x +6.66%
2021-12-31 CN¥4.13 Billion
≈ $603.95 Million
CN¥616.80 Million
≈ $90.26 Million
0.149x -75.22%
2020-12-31 CN¥1.33 Billion
≈ $194.97 Million
CN¥803.55 Million
≈ $117.59 Million
0.603x +693.51%
2019-12-31 CN¥200.02 Million
≈ $29.27 Million
CN¥15.20 Million
≈ $2.22 Million
0.076x +415.63%
2018-12-31 CN¥166.08 Million
≈ $24.30 Million
CN¥-4.00 Million
≈ $-585.21K
-0.024x +5.92%
2017-12-31 CN¥150.82 Million
≈ $22.07 Million
CN¥-3.86 Million
≈ $-564.87K
-0.026x --

About Nanjing Vazyme Biotech Co Ltd

SHG:688105 China Biotechnology
Market Cap
$1.65 Billion
CN¥11.27 Billion CNY
Market Cap Rank
#6921 Global
#1449 in China
Share Price
CN¥21.79
Change (1 day)
+3.07%
52-Week Range
CN¥13.14 - CN¥25.52
All Time High
CN¥119.29
About

Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real… Read more